Skip to Content
Merck
CN

SCP0180

[D-Lys6]-LH-RH

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C59H84N18O13
Molecular Weight:
1253.41
NACRES:
NA.32
UNSPSC Code:
12352209
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥95% (HPLC)

form

lyophilized

composition

Peptide Content, ≥70%

storage condition

protect from light

storage temp.

−20°C

Application

Luteinizing-hormone-releasing hormone (LHRH) (GnRH) is a decapeptide (pyroQHWSYKLRPG-NH2) trophic hormone that regulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. Various analogues have been developed using D-amino acids to increase resistance to degradation. These analogues are used as potential targeting agents in the development of chemotherapies and as possible agonists and antagonist of the LHRH receptor.


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata.
Emons G, Pahwa GS, Brack C, et al.
European Journal of Cancer & Clinical Oncology, 25, 215-221 (1089)
Ana M Bajo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9(10 Pt 1), 3742-3748 (2003-09-25)
The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers. Doxorubicin (DOX) was linked to [D-Lys(6)]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R. We evaluated the
Andreas R Günthert et al.
Breast cancer research and treatment, 87(3), 255-264 (2004-11-06)
More than 50% of human breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH-R). These receptors can be used for targeted chemotherapy with agents like AN-152, in which doxorubicin is linked to analog [D-Lys6]LHRH. We compared the effects of AN-152



Global Trade Item Number

SKUGTIN
SCP0180-5MG04061833025253